Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) have earned an average rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $45.25.

PLSE has been the topic of several research analyst reports. Wall Street Zen downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Needham & Company LLC initiated coverage on Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price target for the company. Canaccord Genuity Group raised their price target on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Finally, Mizuho set a $45.00 price target on Pulse Biosciences in a research note on Monday, August 10th.

Pulse Biosciences Price Performance

Shares of PLSE opened at $50.42 on Monday. The company has a market cap of $3.49 billion, a price-to-earnings ratio of -42.73 and a beta of 1.61. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $50.71. The company has a 50 day moving average of $33.08 and a two-hundred day moving average of $25.93.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. On average, sell-side analysts expect that Pulse Biosciences will post -1.29 EPS for the current year.

Institutional Trading of Pulse Biosciences

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its holdings in shares of Pulse Biosciences by 8.2% during the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after buying an additional 65,884 shares during the last quarter. Cetera Investment Advisers acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $387,000. GSA Capital Partners LLP purchased a new position in Pulse Biosciences in the 2nd quarter worth $290,000. Sanctuary Advisors LLC purchased a new position in Pulse Biosciences in the 4th quarter worth $244,000. Finally, Farther Finance Advisors LLC raised its stake in Pulse Biosciences by 39.2% in the 4th quarter. Farther Finance Advisors LLC now owns 20,373 shares of the company’s stock worth $280,000 after acquiring an additional 5,734 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.